Rhythm Pharmaceuticals (RYTM) grants CSO RSUs and 25,000 stock options

Rhea-AI Filing Summary

Rhythm Pharmaceuticals’ Chief Scientific Officer Alastair Garfield received new equity awards. On February 11, 2026, he was granted 16,650 restricted stock units, each representing one share of common stock, and 25,000 stock options with an exercise price of $98.47 per share.

The restricted stock units vest in four equal 25% installments on February 1, 2027, 2028, 2029 and 2030. The options expire on February 10, 2036 and vest in 16 substantially equal installments, each after three full months of continued service following the grant date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Garfield Alastair

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	16,650	$0.00	--
Grant/Award	Stock Options (Right to Buy)	25,000	$0.00	--

Holdings After Transaction: Restricted Stock Units — 16,650 shares (Direct); Stock Options (Right to Buy) — 25,000 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Garfield Alastair

(Last) (First) (Middle)

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/11/2026		A		16,650		(2)	(2)	Common Stock	16,650	$0	16,650	D
Stock Options (Right to Buy)	$98.47	02/11/2026		A		25,000		(3)	02/10/2036	Common Stock	25,000	$0	25,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

2. The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date.

3. The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

	/s/ Stephen Vander Stoep, attorney-in-fact for Alastair Garfield	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider equity awards did Rhythm Pharmaceuticals (RYTM) grant to its CSO?

Rhythm Pharmaceuticals granted its Chief Scientific Officer Alastair Garfield 16,650 restricted stock units and 25,000 stock options. Both awards were granted on February 11, 2026, as part of his equity compensation and are subject to multi-year vesting schedules tied to continued service.

How do the restricted stock units for RYTM’s CSO vest over time?

The 16,650 restricted stock units vest in four equal 25% installments. Vesting dates are February 1, 2027, 2028, 2029 and 2030. Each vested unit converts into one share of Rhythm Pharmaceuticals common stock, aligning long-term compensation with the company’s equity performance.

What are the key terms of the stock options granted to RYTM’s CSO?

The 25,000 stock options have an exercise price of $98.47 and expire on February 10, 2036. They vest in 16 substantially equal installments, each after three full months of continuous service by Alastair Garfield following the February 11, 2026 grant date.

Does Alastair Garfield directly own the derivative securities reported for RYTM?

Yes. The filing classifies ownership of both the restricted stock units and stock options as direct. This means the awards are held directly by Alastair Garfield, not through an intermediary entity, and are part of his personal equity-based compensation package.

What does each restricted stock unit in the RYTM filing represent?

Each restricted stock unit represents a contingent right to receive one share of Rhythm Pharmaceuticals common stock. Shares are delivered as units vest over time, subject to Garfield’s continued service and the specific vesting dates described in the equity award footnotes.

When were the Rhythm Pharmaceuticals stock options to the CSO granted and when do they start vesting?

The stock options were granted on February 11, 2026, to Alastair Garfield. They vest and become exercisable in 16 substantially equal installments, each triggered by the completion of three full months of successive service to Rhythm Pharmaceuticals after the grant date.